Cancer Letters, Journal Year: 2024, Volume and Issue: 596, P. 217018 - 217018
Published: June 5, 2024
Language: Английский
Cancer Letters, Journal Year: 2024, Volume and Issue: 596, P. 217018 - 217018
Published: June 5, 2024
Language: Английский
Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(3), P. 178 - 191
Published: Jan. 9, 2023
Language: Английский
Citations
202Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: 23(4), P. 301 - 319
Published: March 6, 2024
Language: Английский
Citations
135Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)
Published: Nov. 22, 2023
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and hyperactivation, highlights the potential renormalization as a promising strategy in disease treatment. In recent years, our primary focus has centered on γδ T cell-based immunotherapy, particularly pioneering use allogeneic Vδ2
Language: Английский
Citations
113Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Feb. 15, 2023
Abstract As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy recent years. They extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious tumor patients, become pioneer drugs since they were incorporated into practice. In addition, that infiltrated tissues found to be state exhaustion or anergy, there is upregulation many immune checkpoints (ICs) on their surface, suggesting similar ability respond ICIs as traditional effector T cells. Studies shown targeting ICs can reverse dysfunctional microenvironment (TME) exert effects by improving γδT-cell proliferation activation enhancing cytotoxicity. Clarification functional TME mechanisms underlying interaction with will solidify combined good treatment option.
Language: Английский
Citations
76Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: 24(7), P. 471 - 486
Published: Jan. 25, 2024
Language: Английский
Citations
68Cells, Journal Year: 2024, Volume and Issue: 13(2), P. 146 - 146
Published: Jan. 12, 2024
This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this other malignancies and broader patient populations. However, several limitations remain, including those associated the time-consuming highly personalized manufacturing of autologous CAR-Ts. Technologies establish "off-the-shelf" allogeneic CAR-Ts low alloreactivity currently developed, strong focus on gene-editing technologies. Although these technologies have many advantages, they also limitations, double-strand breaks in DNA safety risks as well lack modulation. As an alternative, non-gene-editing provide interesting approach support development future, possibilities fine-tuning gene expression easy development. Here, we will review different ways can be manufactured discuss which used. The biggest hurdles successful summarized, finally, overview current clinical evidence comparison its counterpart given.
Language: Английский
Citations
21MedComm, Journal Year: 2024, Volume and Issue: 5(10)
Published: Sept. 15, 2024
The innate immune system serves as the body's first line of defense, utilizing pattern recognition receptors like Toll-like to detect pathogens and initiate rapid response mechanisms. Following this initial response, adaptive immunity provides highly specific sustained killing via B cells, T antibodies. Traditionally, it has been assumed that activates immunity; however, recent studies have revealed more complex interactions. This review a detailed dissection composition function systems, emphasizing their synergistic roles in physiological pathological contexts, providing new insights into link between these two forms immunity. Precise regulation both systems at same time is beneficial fight against immune-related diseases, for example, cGAS-STING pathway found play an important role infections cancers. In addition, paper summarizes challenges future directions field immunity, including latest single-cell sequencing technologies, CAR-T cell therapy, checkpoint inhibitors. By summarizing developments, aims enhance our understanding complexity interactions perspectives system.
Language: Английский
Citations
18Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: March 31, 2023
Owing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy recent years. However, many unknowns still exist regarding cells, few clinical data been collected. Therefore, this review aims describe all the main features of applications provide a systematic view current immunotherapy. Specifically, will focus on how performed treating cancers clinics, trials that conducted date, role pharmaceutical industry.
Language: Английский
Citations
30Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: March 21, 2024
Comprising only 1-10% of the circulating T cell population, γδT cells play a pivotal role in cancer immunotherapy due to their unique amalgamation innate and adaptive immune features. These can secrete cytokines, including interferon-γ (IFN-γ) tumor necrosis factor-α (TNF-α), directly eliminate through mechanisms like Fas/FasL antibody-dependent cell-mediated cytotoxicity (ADCC). Unlike conventional αβT cells, target wide variety independently major histocompatibility complex (MHC) presentation function as antigen-presenting (APCs). Their ability recognizing antigens non-MHC restricted manner makes them an ideal candidate for allogeneic immunotherapy. Additionally, exhibit specific tissue tropism, rapid responsiveness upon reaching cellular targets, indicating high level precision adaptability. Despite these capabilities, therapeutic potential has been hindered by some limitations, abundance, unsatisfactory expansion, limited persistence, biology plasticity. To address issues, gene-engineering strategies use chimeric antigen receptor (CAR) therapy, (TCR) gene transfer, combination with engagers are being explored. This review will outline progress various engineering strategies, discuss implications challenges that lie ahead, future directions engineered both monotherapy
Language: Английский
Citations
11ACS Nano, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 25, 2025
Melanoma is the most aggressive type of skin cancers. Traditional chemotherapy and radiotherapy have limited effectiveness can lead to systemic side effects. Photodynamic therapy (PDT) a photoresponsive cancer based on photosensitizers generate reactive oxygen species (ROS) eradicate tumor cells. Our previous study showed that exosomes derived from human γδ-T cells (γδ-T exosomes) could control Epstein–Barr virus-associated tumors. Here, we combined PDT for targeted photoimmunotherapy by membrane fusion Chlorin e6 (Ce6)-loaded liposomes. The functional surface proteins, such as CCR5 PD-1, hybrid mediated specific binding toward melanoma tissues. cytolytic molecules, granzyme A, B, perforin, granulysin exosomes, induced apoptosis without harming normal In response light irradiation, ROS generation inside synergized with molecules induce promote immunogenic cell death (ICD). subsequently released damage-associated molecular patterns (DAMPs) stimulate dendritic maturation antigen-specific CD4+ CD8+ T-cell responses, thereby enhancing antitumor immunity. This provides promising strategy combining photoimmunotherapy, expanding clinical applications exosome patients.
Language: Английский
Citations
1